| Identification and characterization of ovarian cancer-initiating cells from primary human tumors S Zhang, C Balch, MW Chan, HC Lai, D Matei, JM Schilder, PS Yan, ... Cancer research 68 (11), 4311-4320, 2008 | 1689 | 2008 |
| Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer M Li, C Balch, JS Montgomery, M Jeong, JH Chung, P Yan, THM Huang, ... BMC medical genomics 2, 1-13, 2009 | 246 | 2009 |
| A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer F Fang, C Balch, J Schilder, T Breen, S Zhang, C Shen, L Li, ... Cancer 116 (17), 4043-4053, 2010 | 198 | 2010 |
| Minireview: epigenetic changes in ovarian cancer C Balch, F Fang, DE Matei, THM Huang, KP Nephew Endocrinology 150 (9), 4003-4011, 2009 | 174 | 2009 |
| Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance F Xin, M Li, C Balch, M Thomson, M Fan, Y Liu, SM Hammond, S Kim, ... Bioinformatics 25 (4), 430-434, 2009 | 144 | 2009 |
| Growth inhibition of ovarian tumor–initiating cells by niclosamide YT Yo, YW Lin, YC Wang, C Balch, RL Huang, MWY Chan, HK Sytwu, ... Molecular cancer therapeutics 11 (8), 1703-1712, 2012 | 142 | 2012 |
| Detection of PIWI and piRNAs in the mitochondria of mammalian cancer cells CH Kwon, H Tak, M Rho, HR Chang, YH Kim, KT Kim, C Balch, EK Lee, ... Biochemical and biophysical research communications 446 (1), 218-223, 2014 | 84 | 2014 |
| Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications MJ Kwon, SS Kim, YL Choi, HS Jung, C Balch, SH Kim, YS Song, ... Carcinogenesis 31 (6), 974-983, 2010 | 82 | 2010 |
| A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer YT Yang, C Balch, SK Kulp, MR Mand, KP Nephew, CS Chen Neoplasia 11 (6), 552-IN9, 2009 | 68 | 2009 |
| Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells SA Bapat, V Jin, N Berry, C Balch, N Sharma, N Kurrey, S Zhang, F Fang, ... Epigenetics 5 (8), 716-729, 2010 | 65 | 2010 |
| Natural polyphenols in cancer chemoresistance SA Hussain, AA Sulaiman, C Balch, H Chauhan, QM Alhadidi, AK Tiwari Nutrition and cancer 68 (6), 879-891, 2016 | 63 | 2016 |
| Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells K McIntosh, C Balch, AK Tiwari Expert opinion on drug metabolism & toxicology 12 (6), 633-644, 2016 | 58 | 2016 |
| Epigenetic “bivalently marked” process of cancer stem cell‐driven tumorigenesis C Balch, KP Nephew, THM Huang, SA Bapat Bioessays 29 (9), 842-845, 2007 | 51 | 2007 |
| TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions PH Su, YW Hsu, RL Huang, LY Chen, TK Chao, CC Liao, CW Chen, ... Cancer letters 450, 53-62, 2019 | 40 | 2019 |
| A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer S Nam, HR Chang, HR Jung, Y Gim, NY Kim, R Grailhe, HR Seo, HS Park, ... Cancer letters 356 (2), 880-890, 2015 | 39 | 2015 |
| Epigenetic targeting therapies to overcome chemotherapy resistance C Balch, KP Nephew Epigenetic Alterations in Oncogenesis, 285-311, 2012 | 38 | 2012 |
| Pyrimido [1 ″, 2 ″: 1, 5] pyrazolo [3, 4-b] quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells C Karthikeyan, R Malla, CR Ashby Jr, H Amawi, KL Abbott, J Moore, ... Cancer letters 376 (1), 118-126, 2016 | 33 | 2016 |
| The epigenomics of embryonic pathway signaling in colorectal cancer C Balch, JB Ramapuram, AK Tiwari Frontiers in pharmacology 8, 267, 2017 | 30 | 2017 |
| Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer HR Chang, S Nam, J Lee, JH Kim, HR Jung, HS Park, S Park, YZ Ahn, ... Oncotarget 7 (49), 81435, 2016 | 25 | 2016 |
| A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells C Balch, K Naegeli, S Nam, B Ballard, A Hyslop, C Melki, E Reilly, ... Cancer Biology & Therapy 13 (8), 681-693, 2012 | 21 | 2012 |
